The introduction of TKIs targeting the tyrosine kinase activity of the BCR::ABL oncoprotein has transformed the management of CP-CML [27], increasing relative survival rates to a point where CML is no longer considered an incurable disease. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.